H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Icecure Medical (ICCM – Research Report) today and set a price target of $3.00. The company’s shares opened today at $0.52.
According to TipRanks, Chen is an analyst with an average return of -32.0% and a 22.65% success rate. Chen covers the Healthcare sector, focusing on stocks such as Anixa Biosciences, Oculis Holding, and Icecure Medical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Icecure Medical with a $2.97 average price target, a 471.15% upside from current levels. In a report released today, Alliance Global Partners also maintained a Buy rating on the stock with a $1.90 price target.
See Insiders’ Hot Stocks on TipRanks >>
ICCM market cap is currently $50.94M and has a P/E ratio of -1.96.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Icecure Medical (ICCM) Company Description:
Icecure Medical Ltd is a Israel based firm which develops and markets minimally invasive cryoablation therapies for women’s health. The company provides a minimally invasive, in-office definitive treatment for symptomatic breast fibroadenoma.
Read More on ICCM:
- IceCure Medical management to meet with Oppenheimer
- IceCure Medical’s ProSense system receives regulatory approval in Brazil
- IceCure Medical appoints Good as VP of Sales for North America
- IceCure Medical price target lowered to $4 from $4.25 at Alliance Global
- IceCure Medical Reports First Half 2023 Financial & Operational Results: Global Adoption of Cryoablation Technology Gaining Momentum
